Comparative Pharmacology
Head-to-head clinical analysis: BLISOVI 24 FE versus PORTIA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLISOVI 24 FE versus PORTIA 21.
BLISOVI 24 FE vs PORTIA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and drospirenone; primarily suppresses gonadotropins (FSH, LH) via negative feedback, preventing ovulation. Drospirenone has anti-mineralocorticoid and anti-androgenic activity.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
One tablet orally once daily for 24 weeks, followed by placebo tablets for 4 weeks; each tablet contains 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol for 21 days, then 0.01 mg ethinyl estradiol for 3 days, then 2 tablets of 75 mg ferrous fumarate for 5 days.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Drospirenone: 25-33 hours; Ethinyl estradiol: 13-24 hours; steady-state achieved after 10 days.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Renal: 30-40% as drospirenone metabolites, 20-30% as ethinyl estradiol metabolites; fecal: 40-50% as drospirenone metabolites, 30-40% as ethinyl estradiol metabolites; biliary: minimal.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Category C
Category C
Oral Contraceptive
Oral Contraceptive